IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Buy” by Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given an average rating of “Buy” by the seventeen ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $224.1250.

IQV has been the subject of a number of recent research reports. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Truist Financial reduced their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th.

IQVIA Stock Performance

IQVIA stock opened at $186.27 on Wednesday. The company has a 50 day moving average price of $172.86 and a 200-day moving average price of $194.33. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a fifty-two week low of $153.01 and a fifty-two week high of $247.04. The company has a market capitalization of $31.09 billion, a PE ratio of 23.08, a P/E/G ratio of 1.58 and a beta of 1.21.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts forecast that IQVIA will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On IQVIA

Large investors have recently made changes to their positions in the business. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the fourth quarter worth $25,000. Financial Freedom LLC acquired a new position in shares of IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA during the first quarter worth $25,000. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth $27,000. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.